Preventable hospital admissions related to medication (HARM): Cost analysis of the HARM study

Leendertse, Anne J.; Bemt, Patricia M. L. A. van den; Poolman, J. Bart; Stoker, Lennart J.; Egberts, Toine C. G.; Postma, Maarten J.

doi:10.1016/j.jval.2010.10.024

Cited by 100 publications

(87 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Similar figures were found in other countries [5]. In addition, studies conducted among hospitalized patients in The Netherlands and Canada reported ADE rates of 5.6 and 24.1%, respectively [6,7]. Therefore, by timely detection of adverse outcomes associated with drug exposure, PV could be an area of major medical and economic benefits [8].…”

Section: Special Reportsupporting

confidence: 59%

Pharmacogenovigilance: A Pharmacogenomics Pharmacovigilance Program

Awada

Zgheib

2014

Pharmacogenomics

View full text Add to dashboard Cite

In this report, we review the importance of pharmacovigilance in detecting postmarketing adverse drug events and the potential for developing pharmacogenovigilance programs by integrating pharmacogenomics with pharmacovigilance. We propose to start developing such a program in primary healthcare systems that use basic features of electronic medical records and have access to large numbers of patients commonly prescribed drugs. Such programs, if carefully designed, may grow over time and hopefully enhance the collection and interpretation of useful data for the clinical applications of pharmacogenomics testing.

show abstract

Section: Special Reportsupporting

confidence: 59%

Pharmacogenovigilance: A Pharmacogenomics Pharmacovigilance Program

Awada

Zgheib

2014

Pharmacogenomics

View full text Add to dashboard Cite

show abstract

“…Two studies (6.5%) evaluated the costs of ADEs in pediatric population and three studies (9.7%) studied specifically the geriatric population 13–17…”

Section: Resultsmentioning

confidence: 99%

“…The costs of ADEs related to any drug occurring in nonhospitalized patients has been estimated from €702.21 to €40,273.08 13,14,18–29. A study investigated the costs of ADEs related to rhythm-control, rate-control, and combined rhythm-/rate-control medication; the costs per patient with an ADE were estimated to be €2,737.46 21.…”

Section: Resultsmentioning

confidence: 99%

A systematic review of observational studies evaluating costs of adverse drug reactions

Marques¹,

Penedones²,

Mendes³

et al. 2016

CEOR

View full text Add to dashboard Cite

IntroductionThe growing evidence of the increased frequency and severity of adverse drug events (ADEs), besides the negative impact on patient’s health status, indicates that costs due to ADEs may be steadily rising. Observational studies are an important tool in pharmacovigilance. Despite these studies being more susceptible to bias than experimental designs, they are more competent in assessing ADEs and their associated costs.ObjectiveTo identify and characterize the best available evidence on ADE-associated costs.MethodsMEDLINE, Cochrane Library, and Embase were searched from 1995 to 2015. Observational studies were included. The methodological quality of selected studies was assessed by Cochrane Collaboration tool for experimental and observational studies. Studies were classified according to the setting analyzed in “ambulatory”, “hospital”, or both. Costs were classified as “direct” and “indirect”. Data were analyzed using descriptive statistics. The total incremental cost per patient with ADE was estimated.ResultsTwenty-nine (94%) longitudinal observational studies and two (7%) cross-sectional studies were included. Twenty-three (74%) studies were assessed with the highest methodological quality score. The studies were mainly conducted in the US (61%). Twenty (65%) studies evaluated any therapeutic group. Twenty (65%) studies estimated costs of ADEs leading to or prolonging hospitalization. The “direct costs” were evaluated in all studies, whereas only two (7%) also estimated the “indirect costs”. The “direct costs” in ambulatory ranged from €702.21 to €40,273.08, and the in hospital from €943.40 to €7,192.36.DiscussionMethodological heterogeneities were identified among the included studies, such as design, type of ADEs, suspected drugs, and type and structure of costs. Despite such discrepancies, the financial burden associated with ADE costs was found to be high. In the light of the present findings, validated methods to measure ADE-associated costs need future research efforts.

show abstract

“…Patients’ age, patients’ sex, number of errors related to one patient, number of medication orders related to one patient and drug groups, associated with high risk on preventable harm, were considered as potential confounders. Relevant drug groups were selected from both the literature19 and the associations with pADEs in our own data (percentage of pADEs per prescribed drug group). These were antidiabetics, anticoagulants, drugs for anaemia, corticosteroids, antibiotics for systemic use, anti-inflammatory drugs, analgesics, antiepileptics, psycholeptics and drugs for gout.…”

Section: Methodsmentioning

confidence: 99%

Medication errors: the impact of prescribing and transcribing errors on preventable harm in hospitalised patients

Doormaal

Bemt

Mol

et al. 2009

Quality and Safety in Health Care

View full text Add to dashboard Cite

show abstract

Preventable hospital admissions related to medication (HARM): Cost analysis of the HARM study

Abstract: The costs of potentially preventable hospital admissions related to medication are considerable. Therefore, patient safety interventions to prevent ADEs and hospital admissions may be cost-effective or even cost saving.

Cited by 100 publications

References 31 publications

Pharmacogenovigilance: A Pharmacogenomics Pharmacovigilance Program

Pharmacogenovigilance: A Pharmacogenomics Pharmacovigilance Program

A systematic review of observational studies evaluating costs of adverse drug reactions

Medication errors: the impact of prescribing and transcribing errors on preventable harm in hospitalised patients

Contact Info

Product

Resources

About